CoChat

Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance

Open access
Rozengurt, Enrique, Eibl, Guido · 2021 · Cancers
Cited by 30

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, remains a devastating disease. The purpose of this review is to highlight recent literature on mechanistic and translational developments that advance our understanding of a complex crosstalk between KRAS, YAP and Src tyrosine kinase family (SFK) in PDAC development and maintenance. We discuss recent studies indicating the importance of RAS dimerization in signal transduction and new findings showing that the potent pro-oncogenic members of the SFK phosphorylate and inhibit RAS function. These surprising findings imply that RAS may not play a crucial role in maintaining certain subtypes of PDAC. In support of this interpretation, current evidence indicates that the survival of the basal-like subtype of PDAC is less dependent on RAS but relies, at least in part, on the activity of YAP/TAZ. Based on current evidence, we propose that SFK propels PDAC cells to a state of high metastasis, epithelial-mesenchymal transition (EMT) and reduced dependence on KRAS signaling, salient features of the aggressive basal-like/squamous subtype of PDAC. Strategies for PDAC treatment should consider the opposite effects of tyrosine phosphorylation on KRAS and SFK/YAP in the design of drug combinations that target these novel crosstalk mechanisms and overcome drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13205126

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 115

  1. Siegel, 2021, Cancer statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 · DOI · Paper page
  2. Rahib, 2014, Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155 · DOI · Paper page
  3. Garcia-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., and Acedo, P. (2021). The state-of-the-art of phase ii/iii clinical trials for targeted pancreatic cancer therapies. J. Clin. Med., 10. · DOI
  4. Hammad, 2021, Pancreatic adenocarcinoma: Molecular drivers and the role of targeted therapy, Cancer Metastasis Rev., 40, 355, 10.1007/s10555-020-09948-w · DOI
  5. Eyres, 2021, Tet2 drives 5hmc marking of gata6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes, Gastroenterology, 161, 653, 10.1053/j.gastro.2021.04.044 · DOI
  6. Koikawa, 2021, Targeting pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy, Cell, 184, 4753, 10.1016/j.cell.2021.07.020 · DOI · Paper page
  7. Eibl, 2019, Kras, yap, and obesity in pancreatic cancer: A signaling network with multiple loops, Semin. Cancer Biol., 54, 50, 10.1016/j.semcancer.2017.10.007 · DOI · Paper page
  8. Bryant, 2014, Kras: Feeding pancreatic cancer proliferation, Trends Biochem. Sci., 39, 91, 10.1016/j.tibs.2013.12.004 · DOI · Paper page
  9. Rhett, 2020, Biology, pathology, and therapeutic targeting of ras, Adv. Cancer Res., 148, 69, 10.1016/bs.acr.2020.05.002 · DOI
  10. Dhanaraman, 2020, Rassf effectors couple diverse ras subfamily gtpases to the hippo pathway, Sci. Signal., 13, eabb4778, 10.1126/scisignal.abb4778 · DOI
  11. Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
  12. Ardito, 2012, Egf receptor is required for kras-induced pancreatic tumorigenesis, Cancer Cell, 22, 304, 10.1016/j.ccr.2012.07.024 · DOI · Paper page
  13. Maitra, 2005, Precursors to invasive pancreatic cancer, Adv. Anat. Pathol., 12, 81, 10.1097/01.pap.0000155055.14238.25 · DOI · Paper page
  14. Hingorani, 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell, 4, 437, 10.1016/S1535-6108(03)00309-X · DOI · Paper page
  15. Hingorani, 2005, Trp53r172h and krasg12d cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
  16. Ferreira, 2017, Duct- and acinar-derived pancreatic ductal adenocarcinomas show distinct tumor progression and marker expression, Cell Rep., 21, 966, 10.1016/j.celrep.2017.09.093 · DOI · Paper page
  17. Rozengurt, 2019, Central role of yes-associated protein and ww-domain-containing transcriptional co-activator with pdz-binding motif in pancreatic cancer development, World J. Gastroenterol., 25, 1797, 10.3748/wjg.v25.i15.1797 · DOI
  18. Kim, 2021, Oncogenic kras recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis, Cancer Discov., 11, 2094, 10.1158/2159-8290.CD-20-1228 · DOI · Paper page
  19. Rudack, 2021, The ras dimer structure, Chem. Sci., 12, 8178, 10.1039/D1SC00957E · DOI
  20. Rajakulendran, 2009, A dimerization-dependent mechanism drives raf catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
  21. Nussinov, 2019, Is nanoclustering essential for all oncogenic kras pathways? Can it explain why wild-type kras can inhibit its oncogenic variant?, Semin. Cancer Biol., 54, 114, 10.1016/j.semcancer.2018.01.002 · DOI
  22. Terrell, 2019, Ras-mediated activation of the raf family kinases, Cold Spring Harb. Perspect. Med., 9, a033746, 10.1101/cshperspect.a033746 · DOI · Paper page
  23. Lavoie, 2015, Regulation of raf protein kinases in erk signalling, Nat. Rev. Mol. Cell Biol., 16, 281, 10.1038/nrm3979 · DOI · Paper page
  24. Tran, 2021, Kras interaction with raf1 ras-binding domain and cysteine-rich domain provides insights into ras-mediated raf activation, Nat. Commun., 12, 1176, 10.1038/s41467-021-21422-x · DOI · Paper page
  25. Brummer, 2020, Raf kinase dimerization: Implications for drug discovery and clinical outcomes, Oncogene, 39, 4155, 10.1038/s41388-020-1263-y · DOI
  26. Van, Q.N., Prakash, P., Shrestha, R., Balius, T.E., Turbyville, T.J., and Stephen, A.G. (2021). Ras nanoclusters: Dynamic signaling platforms amenable to therapeutic intervention. Biomolecules, 11. · DOI
  27. Guha, 2003, Neurotensin stimulates protein kinase c-dependent mitogenic signaling in human pancreatic carcinoma cell line panc-1, Cancer Res., 63, 2379
  28. Mueller, 2018, Evolutionary routes and kras dosage define pancreatic cancer phenotypes, Nature, 554, 62, 10.1038/nature25459 · DOI · Paper page
  29. Rozengurt, 2018, Yes-associated protein (yap) in pancreatic cancer: At the epicenter of a targetable signaling network associated with patient survival, Signal Transduct. Target. Ther., 3, 11, 10.1038/s41392-017-0005-2 · DOI · Paper page
  30. Je, 2014, The inhibition of src family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion, Pancreas, 43, 768, 10.1097/MPA.0000000000000103 · DOI · Paper page
  31. Ortiz, 2021, Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition, Cell Commun. Signal., 19, 67, 10.1186/s12964-021-00750-x · DOI · Paper page
  32. Buday, 2020, Novel regulation of ras proteins by direct tyrosine phosphorylation and dephosphorylation, Cancer Metastasis Rev., 39, 1067, 10.1007/s10555-020-09918-2 · DOI
  33. Bunda, 2014, Src promotes gtpase activity of ras via tyrosine 32 phosphorylation, Proc. Natl. Acad. Sci. USA, 111, E3785, 10.1073/pnas.1406559111 · DOI · Paper page
  34. Huang, 2020, Ptpn2 regulates the activation of kras and plays a critical role in proliferation and survival of kras-driven cancer cells, J. Biol. Chem., 295, 18343, 10.1074/jbc.RA119.011060 · DOI
  35. Fodor, 2018, Dual allosteric inhibition of shp2 phosphatase, ACS Chem. Biol., 13, 647, 10.1021/acschembio.7b00980 · DOI · Paper page
  36. Rozengurt, 2014, Suppression of feedback loops mediated by pi3k/mtor induces multiple overactivation of compensatory pathways: An unintended consequence leading to drug resistance, Mol. Cancer Ther., 13, 2477, 10.1158/1535-7163.MCT-14-0330 · DOI · Paper page
  37. Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat. Med., 17, 500, 10.1038/nm.2344 · DOI · Paper page
  38. Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 · DOI · Paper page
  39. Martens, 2019, Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications, Ann. Oncol., 30, 1428, 10.1093/annonc/mdz181 · DOI
  40. Martinelli, 2017, Gata6 regulates emt and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer, Gut, 66, 1665, 10.1136/gutjnl-2015-311256 · DOI · Paper page
  41. Duan, 2021, The value of gata6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer, Sci. Rep., 11, 14951, 10.1038/s41598-021-94544-3 · DOI
  42. Birnbaum, 2021, Transcriptomic analysis of laser capture microdissected tumors reveals cancer- and stromal-specific molecular subtypes of pancreatic ductal adenocarcinoma, Clin. Cancer Res., 27, 2314, 10.1158/1078-0432.CCR-20-1039 · DOI
  43. Juiz, 2020, Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype, FASEB J., 34, 12214, 10.1096/fj.202000363RR · DOI · Paper page
  44. Milan, 2021, Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: A tale of two cell types and their many variants, EMBO J., 40, e107206, 10.15252/embj.2020107206 · DOI
  45. Hayashi, 2020, A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma, Nat. Cancer, 1, 59, 10.1038/s43018-019-0010-1 · DOI · Paper page
  46. Miyabayashi, 2020, Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes, Cancer Discov., 10, 1566, 10.1158/2159-8290.CD-20-0133 · DOI · Paper page
  47. Singh, 2009, A gene expression signature associated with “k-ras addiction” reveals regulators of emt and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
  48. Chen, 2021, Emerging strategies to target ras signaling in human cancer therapy, J. Hematol. Oncol., 14, 116, 10.1186/s13045-021-01127-w · DOI · Paper page
  49. Kerk, 2021, Metabolic networks in mutant kras-driven tumours: Tissue specificities and the microenvironment, Nat. Rev. Cancer, 21, 510, 10.1038/s41568-021-00375-9 · DOI · Paper page
  50. Kanai, 2000, Taz: A novel transcriptional co-activator regulated by interactions with 14-3-3 and pdz domain proteins, EMBO J., 19, 6778, 10.1093/emboj/19.24.6778 · DOI · Paper page
  51. Santinon, 2016, Control of yap/taz activity by metabolic and nutrient-sensing pathways, Trends Cell Biol., 26, 289, 10.1016/j.tcb.2015.11.004 · DOI · Paper page
  52. Zanconato, 2019, Yap and taz: A signalling hub of the tumour microenvironment, Nat. Rev. Cancer, 19, 454, 10.1038/s41568-019-0168-y · DOI · Paper page
  53. Thompson, 2020, Yap/taz: Drivers of tumor growth, metastasis, and resistance to therapy, Bioessays, 42, e1900162, 10.1002/bies.201900162 · DOI · Paper page
  54. Park, 2019, Switch-like enhancement of epithelial-mesenchymal transition by yap through feedback regulation of wt1 and rho-family gtpases, Nat. Commun., 10, 2797, 10.1038/s41467-019-10729-5 · DOI · Paper page
  55. Greenhough, 2018, Cancer cell adaptation to hypoxia involves a hif-gprc5a-yap axis, EMBO Mol. Med., 10, e8699, 10.15252/emmm.201708699 · DOI · Paper page
  56. Gundogdu, R., and Hergovich, A. (2019). Mob (mps one binder) proteins in the hippo pathway and cancer. Cells, 8. · DOI
  57. Wang, 2014, Interplay of mevalonate and hippo pathways regulates rhamm transcription via yap to modulate breast cancer cell motility, Proc. Natl. Acad. Sci. USA, 111, E89
  58. Zheng, 2015, Identification of happyhour/map4k as alternative hpo/mst-like kinases in the hippo kinase cascade, Dev. Cell, 34, 642, 10.1016/j.devcel.2015.08.014 · DOI · Paper page
  59. Meng, 2015, Map4k family kinases act in parallel to mst1/2 to activate lats1/2 in the hippo pathway, Nat. Commun., 6, 8357, 10.1038/ncomms9357 · DOI · Paper page
  60. Hergovich, A. (2016). The roles of ndr protein kinases in hippo signalling. Genes, 7. · DOI · Paper page
  61. McCollum, 2018, Angiomotins stimulate lats kinase autophosphorylation and act as scaffolds that promote hippo signaling, J. Biol. Chem., 293, 18230, 10.1074/jbc.RA118.004187 · DOI
  62. Höffken, V., Hermann, A., Pavenstädt, H., and Kremerskothen, J. (2021). Wwc proteins: Important regulators of hippo signaling in cancer. Cancers, 13. · DOI
  63. Plouffe, 2018, The hippo pathway effector proteins yap and taz have both distinct and overlapping functions in the cell, J. Biol. Chem., 293, 11230, 10.1074/jbc.RA118.002715 · DOI · Paper page
  64. Moroishi, 2015, The emerging roles of yap and taz in cancer, Nat. Rev. Cancer, 15, 73, 10.1038/nrc3876 · DOI · Paper page
  65. Kaan, 2017, Crystal structure of taz-tead complex reveals a distinct interaction mode from that of yap-tead complex, Sci. Rep., 7, 2035, 10.1038/s41598-017-02219-9 · DOI · Paper page
  66. Strauss, 2015, Taz protein accumulation is negatively regulated by yap abundance in mammalian cells, J. Biol. Chem., 290, 27928, 10.1074/jbc.M115.692285 · DOI
  67. Yu, 2013, The hippo pathway: Regulators and regulations, Genes Dev., 27, 355, 10.1101/gad.210773.112 · DOI · Paper page
  68. Tiebe, 2012, Insulin/igf signaling drives cell proliferation in part via yorkie/yap, Dev. Biol., 367, 187, 10.1016/j.ydbio.2012.05.008 · DOI
  69. Wang, 2016, Biphasic regulation of yes-associated protein (yap) cellular localization, phosphorylation, and activity by g protein-coupled receptor agonists in intestinal epithelial cells: A novel role for protein kinase d (pkd), J. Biol. Chem., 291, 17988, 10.1074/jbc.M115.711275 · DOI
  70. Sudol, 2013, Yap1 oncogene and its eight isoforms, Oncogene, 32, 3922, 10.1038/onc.2012.520 · DOI
  71. Ben, 2020, Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of yap1, J. Biol. Chem., 295, 13965, 10.1074/jbc.RA120.013820 · DOI
  72. Cho, 2021, Hippo-independent regulation of yki/yap/taz: A non-canonical view, Front. Cell Dev. Biol., 9, 658481, 10.3389/fcell.2021.658481 · DOI
  73. Yang, 2013, Cdk1 phosphorylation of yap promotes mitotic defects and cell motility and is essential for neoplastic transformation, Cancer Res., 73, 6722, 10.1158/0008-5472.CAN-13-2049 · DOI · Paper page
  74. Cho, 2020, Cdk7 regulates organ size and tumor growth by safeguarding the hippo pathway effector yki/yap/taz in the nucleus, Genes Dev., 34, 53, 10.1101/gad.333146.119 · DOI
  75. Seo, 2019, Mk5 regulates yap stability and is a molecular target in yap-driven cancers, Cancer Res., 79, 6139, 10.1158/0008-5472.CAN-19-1339 · DOI
  76. An, 2020, Mst4 kinase suppresses gastric tumorigenesis by limiting yap activation via a non-canonical pathway, J. Exp. Med., 217, e20191817, 10.1084/jem.20191817 · DOI
  77. Moon, 2017, Phosphorylation by nlk inhibits yap-14-3-3-interactions and induces its nuclear localization, EMBO Rep., 18, 61, 10.15252/embr.201642683 · DOI · Paper page
  78. Xie, 2015, Hippo transducer taz promotes epithelial mesenchymal transition and supports pancreatic cancer progression, Oncotarget, 6, 35949, 10.18632/oncotarget.5772 · DOI
  79. Yang, 2015, Active yap promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through lpar3, Oncotarget, 6, 36019, 10.18632/oncotarget.5935 · DOI · Paper page
  80. Hernandez, 2017, Overexpression of yes associated protein 1, an independent prognostic marker in patients with pancreatic ductal adenocarcinoma, correlated with liver metastasis and poor prognosis, Pancreas, 46, 913, 10.1097/MPA.0000000000000867 · DOI
  81. Zhang, 2014, Downstream of mutant kras, the transcription regulator yap is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci. Signal., 7, ra42, 10.1126/scisignal.2005049 · DOI · Paper page
  82. Gruber, 2016, Yap1 and taz control pancreatic cancer initiation in mice by direct up-regulation of jak–stat3 signaling, Gastroenterology, 151, 526, 10.1053/j.gastro.2016.05.006 · DOI · Paper page
  83. Tamura, T., Kodama, T., Sato, K., Murai, K., Yoshioka, T., Shigekawa, M., Yamada, R., Hikita, H., Sakamori, R., and Akita, H. (2021). Dysregulation of pi3k and hippo signaling pathways synergistically induces chronic pancreatitis via ctgf upregulation. J. Clin. Invest., 131. · DOI
  84. Murakami, 2019, A yap-myc-sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in kras-driven pancreatic ductal adenocarcinomas, Dev. Cell, 51, 113, 10.1016/j.devcel.2019.07.022 · DOI · Paper page
  85. Murakami, 2017, Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma, Oncogene, 36, 1232, 10.1038/onc.2016.288 · DOI · Paper page
  86. King, 2020, Yap/taz promote the scavenging of extracellular nutrients through macropinocytosis, Genes Dev., 34, 1345, 10.1101/gad.340661.120 · DOI
  87. Park, 2020, Yap and ap-1 cooperate to initiate pancreatic cancer development from ductal cells in mice, Cancer Res., 80, 4768, 10.1158/0008-5472.CAN-20-0907 · DOI
  88. Liu, J., Gao, M., Nipper, M., Deng, J., Sharkey, F.E., Johnson, R.L., Crawford, H.C., Chen, Y., and Wang, P. (2019). Activation of the intrinsic fibroinflammatory program in adult pancreatic acinar cells triggered by hippo signaling disruption. PLoS Biol., 17. · DOI
  89. Park, 2015, Alternative wnt signaling activates yap/taz, Cell, 162, 780, 10.1016/j.cell.2015.07.013 · DOI · Paper page
  90. Bo, 2016, Upregulation of the expression of wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model, Mol. Med. Rep., 13, 1163, 10.3892/mmr.2015.4642 · DOI
  91. Lehmann, 2016, Zeb1 turns into a transcriptional activator by interacting with yap1 in aggressive cancer types, Nat. Commun., 7, 10498, 10.1038/ncomms10498 · DOI · Paper page
  92. Liu, 2021, Zinc-dependent regulation of zeb1 and yap1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer, Gastroenterology, 160, 1771, 10.1053/j.gastro.2020.12.077 · DOI · Paper page
  93. Krebs, 2017, The emt-activator zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer, Nat. Cell Biol., 19, 518, 10.1038/ncb3513 · DOI · Paper page
  94. Chang, 2018, The swi/snf complex is a mechanoregulated inhibitor of yap and taz, Nature, 563, 265, 10.1038/s41586-018-0658-1 · DOI · Paper page
  95. Raj, 2019, Reciprocal crosstalk between yap1/hippo pathway and the p53 family proteins: Mechanisms and outcomes in cancer, Front. Cell Dev. Biol., 7, 159, 10.3389/fcell.2019.00159 · DOI
  96. Saladi, 2017, Actl6a is co-amplified with p63 in squamous cell carcinoma to drive yap activation, regenerative proliferation, and poor prognosis, Cancer Cell, 31, 35, 10.1016/j.ccell.2016.12.001 · DOI · Paper page
  97. Lee, 2020, The tumor suppressor bap1 regulates the hippo pathway in pancreatic ductal adenocarcinoma, Cancer Res., 80, 1656, 10.1158/0008-5472.CAN-19-1704 · DOI
  98. Hasan, N., and Ahuja, N. (2019). The emerging roles of atp-dependent chromatin remodeling complexes in pancreatic cancer. Cancers, 11. · DOI
  99. Hao, 2017, Insulin receptor and gpcr crosstalk stimulates yap via pi3k and pkd in pancreatic cancer cells, Mol. Cancer Res., 15, 929, 10.1158/1541-7786.MCR-17-0023 · DOI · Paper page
  100. Kisfalvi, 2009, Metformin disrupts crosstalk between g protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth, Cancer Res., 69, 6539, 10.1158/0008-5472.CAN-09-0418 · DOI · Paper page
  101. Mayer, 2010, Advances in targeting src in the treatment of breast cancer and other solid malignancies, Clin. Cancer Res., 16, 3526, 10.1158/1078-0432.CCR-09-1834 · DOI · Paper page
  102. Roskoski, 2015, Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors, Pharmacol. Res., 94, 9, 10.1016/j.phrs.2015.01.003 · DOI · Paper page
  103. Moro, 2020, Epigenetic silencing of the ubiquitin ligase subunit fbxl7 impairs c-src degradation and promotes epithelial-to-mesenchymal transition and metastasis, Nat. Cell Biol., 22, 1130, 10.1038/s41556-020-0560-6 · DOI
  104. Parkin, 2019, Targeting the complexity of src signalling in the tumour microenvironment of pancreatic cancer: From mechanism to therapy, FEBS J., 286, 3510, 10.1111/febs.15011 · DOI
  105. Morton, 2010, Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma, Gastroenterology, 139, 292, 10.1053/j.gastro.2010.03.034 · DOI · Paper page
  106. Shields, 2011, Oncogenic ras/src cooperativity in pancreatic neoplasia, Oncogene, 30, 2123, 10.1038/onc.2010.589 · DOI · Paper page
  107. Dosch, 2019, Src kinase inhibition restores e-cadherin expression in dasatinib-sensitive pancreatic cancer cells, Oncotarget, 10, 1056, 10.18632/oncotarget.26621 · DOI
  108. Ye, 2015, Epithelial-mesenchymal plasticity: A central regulator of cancer progression, Trends Cell Biol., 25, 675, 10.1016/j.tcb.2015.07.012 · DOI · Paper page
  109. Si, 2017, Src inhibits the hippo tumor suppressor pathway through tyrosine phosphorylation of lats1, Cancer Res., 77, 4868, 10.1158/0008-5472.CAN-17-0391 · DOI · Paper page
  110. Buckarma, 2020, The yap-interacting phosphatase shp2 can regulate transcriptional coactivity and modulate sensitivity to chemotherapy in cholangiocarcinoma, Mol. Cancer Res., 18, 1574, 10.1158/1541-7786.MCR-20-0165 · DOI
  111. Mettu, 2019, A phase i study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (gdc) in refractory solid tumors, Cancer Chemother. Pharmacol., 83, 1025, 10.1007/s00280-019-03805-6 · DOI
  112. Evans, 2017, Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer, Ann. Oncol., 28, 354, 10.1093/annonc/mdw607 · DOI
  113. George, 2021, Phase ii study of 5-fluorouracil, oxaliplatin plus dasatinib (folfox-d) in first-line metastatic pancreatic adenocarcinoma, Oncologist, 26, 825.e1674, 10.1002/onco.13853 · DOI
  114. Infante, 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral mek inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur. J. Cancer, 50, 2072, 10.1016/j.ejca.2014.04.024 · DOI · Paper page
  115. Witkiewicz, 2016, Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer, Cell Rep., 16, 2017, 10.1016/j.celrep.2016.07.023 · DOI · Paper page

Cited by

See all 30

Metadata

Authors
Rozengurt, E., & Eibl, G.
Venue
Cancers
Publisher
MDPI AG
Published
2021-10-13
Volume
13
Issue
20
Pages
5126
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3206563978
Cited by
30
References
65
FWCI
1.88
Type
journal article
Language
en
Open access
gold
Funders
  • National Institutes of Health (P01CA236585, R21AI156592)
  • Veterans Health Administration (I01BX003801)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. https://app.cochat.ai/papers/10.3390/cancers13205126
The paper
Rozengurt, E., & Eibl, G. (2021). Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers. https://doi.org/10.3390/cancers13205126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.